Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies

Daniel C Osei-Bordom; Nikolaos Serifis; Zachary J Brown; D Brock Hewitt; Gbemisola Lawal; Gagandeep Sachdeva; Daniel J Cloonan; Timothy M Pawlik

doi:10.1016/j.suronc.2022.101803

Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies

Surg Oncol. 2022 Aug:43:101803. doi: 10.1016/j.suronc.2022.101803. Epub 2022 Jul 7.

Authors

Daniel C Osei-Bordom¹, Nikolaos Serifis², Zachary J Brown³, D Brock Hewitt³, Gbemisola Lawal⁴, Gagandeep Sachdeva⁵, Daniel J Cloonan⁶, Timothy M Pawlik⁷

Affiliations

¹ Department of General Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, UK.
² Division of Transplantation, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
³ Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
⁴ Department of Surgery, Arrowhead Regional Cancer Center, California University of Science and Medicine, Colton, CA, USA.
⁵ Department of General Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK.
⁶ Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
⁷ Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: tim.pawlik@osumc.edu.

PMID: 35830772
DOI: 10.1016/j.suronc.2022.101803

Abstract

The seventh leading cause of cancer-related death globally, pancreatic ductal adenocarcinoma (PDAC) involves the exocrine pancreas and constitutes greater than 90% of all pancreatic cancers. Surgical resection in combination with systemic chemotherapy with or without radiation remains the mainstay of treatment and the only potentially curative treatment option. While there has been improvement in systemic chemotherapy, long-term survival among patients with PDAC remains poor. Improvement in the understanding of tumorigenesis, genetic mutations, the tumor microenvironment (TME), immunotherapies, as well as targeted therapies continued to drive advances in PDAC treatment. We herein review the TME, genetic landscape, as well as various metabolic pathways associated with PDAC tumorigenesis relative to emerging therapies.

Keywords: Biological agents; Immunotherapy; Pancreatic ductal adenocarcinoma; Therapeutics.

Publication types

Review

MeSH terms

Carcinogenesis
Carcinoma, Pancreatic Ductal* / genetics
Carcinoma, Pancreatic Ductal* / therapy
Humans
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / therapy
Tumor Microenvironment